{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:27:01Z","timestamp":1762432021395,"version":"3.41.2"},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of allografts from hepatitis C virus (HCV) Nucleic Acid Testing (NAT)+ donors into HCV NAT\u2010 recipients has been reported to be efficacious in a handful of studies. However, these studies have not reflected real\u2010world practice where the initiation of direct\u2010acting antivirals (DAA) is dependent on insurance coverage. A single\u2010center, retrospective chart review of HCV NAT\u2010 recipients who underwent solid organ transplantation (SOT) from a HCV NAT+ donor between April 1, 2019 and May 27, 2020 was conducted. Sixty\u2010one HCV NAT\u2010 patients underwent SOT with a HCV NAT+ organ, with 59 transplant recipients included for evaluation: 22 kidney (KT), 18 liver (LiT), 10 heart (HT), nine lung (LuT). HCV transmission occurred in 100% of recipients. Average time to DAA initiation was POD 46.3 \u00b1 25 days. SVR12 was achieved in 98% (56\/57; two patients ineligible for analysis). Treatment failure occurred in one LuT on glecaprevir\/pibrentasvir with P32del and Q80K mutations. No patients developed fibrosing cholestatic hepatitis. Two patients died, secondary to anastomotic complication (LuT) and pulmonary embolism (HT). Clinically significant rejection was diagnosed and treated in two HT (one patient with ACR2 and one with ACR2\/pAMR2) and one LiT (RAI 5\/9). Six patients (10.2%) had documented adverse effects attributed to DAA therapy, primarily gastrointestinal.<\/jats:p>","DOI":"10.1111\/ctr.14386","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T10:50:35Z","timestamp":1623840635000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct\u2010acting antiviral initiation"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3549-3509","authenticated-orcid":false,"given":"Madeline R.","family":"Hudson","sequence":"first","affiliation":[{"name":"Department of Pharmacy Tampa General Hospital  Tampa Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allyssa R.","family":"Webb","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Tampa General Hospital  Tampa Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Tong","family":"Logan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Tampa General Hospital  Tampa Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Silverman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Tampa General Hospital  Tampa Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Brueckner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Tampa General Hospital  Tampa Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6,27]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"National Data.Organ Procurement and Transplantation Network.https:\/\/optn.transplant.hrsa.gov\/data\/view\u2010data\u2010reports\/national\u2010data\/Published November 26 2020. Accessed November 26 2020."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1901957"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14381"},{"key":"e_1_2_7_5_1","unstructured":"Treatment of HCV\u2010Uninfected Transplant Recipients Receiving Organs From HCV\u2010Viremic Donors. Hcvguidelines.org.https:\/\/www.hcvguidelines.org\/unique\u2010populations\/organs\u2010from\u2010hcv\u2010viremic\u2010donorsPublished August 27 2020. Accessed November 25 2020."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13194"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15162"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15496"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13833"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15664"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0749"},{"issue":"11","key":"e_1_2_7_12_1","first-page":"1105","article-title":"THINKER trial investigators. Transplanting HCV\u2010infected kidneys into uninfected recipients","volume":"377","author":"Goldberg DS","year":"2017","journal-title":"N Engl J Med"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812406"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30081-9"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.03.004"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13761"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31011"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201712-2614LE"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30268-1"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2018.01.1293"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.4748"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.14386","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ctr.14386","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.14386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T03:49:17Z","timestamp":1693280957000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.14386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,27]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1111\/ctr.14386"],"URL":"https:\/\/doi.org\/10.1111\/ctr.14386","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"type":"print","value":"0902-0063"},{"type":"electronic","value":"1399-0012"}],"subject":[],"published":{"date-parts":[[2021,6,27]]},"assertion":[{"value":"2021-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14386"}}